Top

Archives of Osteoporosis

Published in:

Open Access 01-12-2017 | Original Article

Impact of gastrointestinal events on patient-reported outcomes in Asia-Pacific women with osteoporosis: baseline results of the MUSIC OS-AP study

Authors: A. Modi, P. R. Ebeling, M. S. Lee, Y. K. Min, A. Mithal, X. Yang, S. Baidya, S. Sen, S. Sajjan

Published in: Archives of Osteoporosis | Issue 1/2017

Abstract

Summary

The purpose of this study was to describe the impact of gastrointestinal events on patient-reported outcomes and health care resource use among Asia-Pacific women with postmenopausal osteoporosis. The results of this study show that gastrointestinal events decreased adherence, treatment satisfaction, and quality of life in Asia-Pacific women with postmenopausal osteoporosis.

Purpose

This study aimed to describe the impact of gastrointestinal (GI) events on patient-reported outcomes and health care resource use among Asia-Pacific women with postmenopausal osteoporosis.

Methods

The MUSIC OS-AP study included an observational cohort study of postmenopausal women with osteoporosis. Women were classified as untreated or treated, with treated patients further classified as new or experienced users. Adherence was measured by the Adherence Evaluation of Osteoporosis treatment (ADEOS) questionnaire, treatment satisfaction by the Osteoporosis Patient Satisfaction Questionnaire (OPSAT) while general health-related and osteoporosis-specific quality of life were measured by the European Quality of Life-5 Dimensions (EQ-5D) questionnaire and the Osteoporosis Assessment Questionnaire (OPAQ), respectively. The association of GI events with these outcomes was determined by covariate-adjusted regression analysis of least squares mean differences in the scores of treated patients with and without GI events. Resource utilization was measured as the number of physician visits over the past 3 months, and multivariate regression analysis was used to assess the association of GI events with the likelihood of a visit.

Results

The GI event profile, quality of life scores, and resource use were numerically similar in untreated and treated women. The rate of adherence among treated women was higher in experienced than in new users. As indicated by mean scores, experienced users had better quality of life and slightly higher treatment satisfaction and fewer physician visits than new users. Except for adherence in new users, all measures were similarly adversely affected by GI events in both new and experienced users.

Conclusions

GI events decreased adherence, treatment satisfaction, and quality of life in Asia-Pacific women with postmenopausal osteoporosis.

Mithal A, Dhingra V, Lau E (2009) The Asian Audit- Epidemiology, costs and burden of osteoporosis in Asia 2009: A report of International Osteoporosis Foundation 2009. https://www.iofbonehealth.org/sites/default/files/PDFs/Audit%20Asia/Asian_regional_audit_2009.pdf. Accesssed 15 Feb 2015

Wade SW, Strader C, Fitzpatrick LA, Anthony MS, O’Malley CD (2014) Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos 9:182. doi:10.1007/s11657-014-0182-3 CrossRefPubMed

Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216CrossRefPubMed

Ringe JD, Moller G (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 30:213–221. doi:10.1007/s00296-009-0940-5 CrossRefPubMed

Payer J, Cierny D, Killinger Z, Sulkova I, Behuliak M, Celec P (2009) Preferences of patients with post-menopausal osteoporosis treated with bisphosphonates—the VIVA II study. J Int Med Res 37:1225–1229CrossRefPubMed

Lo JC, Pressman AR, Omar MA, Ettinger B (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922–928. doi:10.1007/s00198-006-0085-2 CrossRefPubMed

Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921. doi:10.1007/s00198-006-0073-6 CrossRefPubMed

Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 24:1337–1344. doi:10.1185/030079908X297358 CrossRefPubMed

Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569–1575. doi:10.1359/jbmr.080510 CrossRefPubMed

10.

Modi A, Siris S, Yang X, Fan CP, Sajjan S (2015) Association between gastrointestinal events and persistence with osteoporosis therapy: analysis of administrative claims of a U.S. managed care population. J Manag Care Spec Pharm 21:499–506. doi:10.18553/jmcp.2015.21.6.499

11.

Yun H, Curtis JR, Guo L, Kilgore M, Muntner P, Saag K, Matthews R, Morrisey M, Wright NC, Becker DJ, Delzell E (2014) Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries. BMC Musculoskelet Disord 15:112. doi:10.1186/1471-2474-15-112 CrossRefPubMedPubMedCentral

12.

Binkley N, Martens MG, Silverman SL, Derman RJ, Greenwald M, Kohles JD, Bachmann GA (2009) Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates. South Med J 102:486–492. doi:10.1097/SMJ.0b013e31819ed0dd CrossRefPubMed

13.

Woo C, Gao G, Wade S, Hochberg MC (2010) Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study. Curr Med Res Opin 26:1003–1009. doi:10.1185/03007991003633603 CrossRefPubMed

14.

Turbi C, Herrero-Beaumont G, Acebes JC, Torrijos A, Grana J, Miguelez R, Sacristan J, Marin F (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26:245–256CrossRefPubMed

15.

Blumentals WA, Harris ST, Cole RE, Huang L, Silverman SL (2009) Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. Ann Pharmacother 43:577–585. doi:10.1345/aph.1L555 CrossRefPubMed

16.

Landfeldt E, Lang A, Robbins S, Strom O (2011) Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish adherence register analysis (SARA). Calcif Tissue Int 89:234–245. doi:10.1007/s00223-011-9511-3 CrossRefPubMed

17.

Modi A, Ebeling P, Lee MS, Min YK, Mithal A, Yang X, Sajjan S (2015) Medication use patterns, treatment satisfaction, and inadequate control of osteoporosis study in the Asia-Pacific region (MUSIC OS-AP): design of a multinational, prospective, observational study examining the impact of gastrointestinal events on osteoporosis management in postmenopausal women. Bone Rep 3:61–66. doi:10.1016/j.bonr.2015.09.002 CrossRefPubMedPubMedCentral

18.

Breuil V, Cortet B, Cotte FE, Arnould B, Dias-Barbosa C, Gaudin AF, Regnault A, Roborel de Climens A, Legrand E (2012) Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporos Int 23:445–455. doi:10.1007/s00198-011-1555-8 CrossRefPubMed

19.

Flood EM, Beusterien KM, Green H, Shikiar R, Baran RW, Amonkar MM, Cella D (2006) Psychometric evaluation of the osteoporosis patient treatment satisfaction questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health Qual Life Outcomes 4:42. doi:10.1186/1477-7525-4-42 CrossRefPubMedPubMedCentral

20.

Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol group. Ann Med 33:337–343CrossRefPubMed

21.

Walters SJ, Brazier JE (2005) Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 14:1523–1532CrossRefPubMed

22.

Sullivan PW, Lawrence WF, Ghushchyan V (2005) A national catalog of preference-based scores for chronic conditions in the United States. Med Care 43:736–749CrossRefPubMed

23.

Silverman S (2000) The osteoporosis assessment questionnaire (OPAQ): a reliable and valid disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis. Qual Life Res 9:767–774. doi:10.1023/A:1008934208764 CrossRef

24.

Nixon A, Kerr C, Doll H, Naegeli AN, Shingler SL, Breheny K, Burge R, Gold DT, Silverman S (2014) Osteoporosis assessment questionnaire-physical function (OPAQ-PF): a psychometrically validated osteoporosis-targeted patient reported outcome measure of daily activities of physical function. Osteoporos Int 25:1775–1784. doi:10.1007/s00198-014-2695-4 CrossRefPubMedPubMedCentral

25.

Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, Yanagimoto K, Sakota K (2007) Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 25:302–309. doi:10.1007/s00774-007-0768-6 CrossRefPubMed

26.

Ideguchi H, Ohno S, Takase K, Ueda A, Ishigatsubo Y (2008) Outcomes after switching from one bisphosphonate to another in 146 patients at a single university hospital. Osteoporos Int 19:1777–1783. doi:10.1007/s00198-008-0618-y CrossRefPubMed

27.

Modi A, Sen S, Adachi JD, Adami S, Cortet B, Cooper AL, Geusens P, Mellstrom D, Weaver J, van den Bergh JP, Nguyen AM, Sajjan S, Group M-OS (2016) Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study. Osteoporos Int 27:1227–1238. doi:10.1007/s00198-015-3388-3 CrossRefPubMed

28.

Oh KW, Kim DY, Lee YS, Kang MI (2012) Osteoporosis patient treatment satisfaction questionnaire in postmenopausal women intermittently treated with oral bisphosphonates: the BRAVO study. J Bone Miner Metab 30:359–366. doi:10.1007/s00774-011-0326-0 CrossRefPubMed

29.

Chung YS, Lim SK, Chung HY, Lee IK, Park IH, Kim GS, Min YK, Kang MI, Chung DJ, Kim YK, Choi WH, Shong MH, Park JH, Byun DW, Yoon HK, Shin CS, Lee YS, Kwon NH (2009) Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women. Calcif Tissue Int 85:389–397. doi:10.1007/s00223-009-9294-y CrossRefPubMedPubMedCentral

30.

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM (2010) American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 16(Suppl 3):1–37CrossRefPubMedPubMedCentral

31.

MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197–213CrossRefPubMed

32.

Kanis JA, On behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. World Health Organization Collaborating Centre for metabolic bone diseases. University of Sheffield, United Kingdom

33.

Chang FY, Chen PH, Wu TC, Pan WH, Chang HY, Wu SJ, Yeh NH, Tang RB, Wu L, James FE (2012) Prevalence of functional gastrointestinal disorders in Taiwan: questionnaire-based survey for adults based on the Rome III criteria. Asia Pac J Clin Nutr 21:594–600PubMed

34.

Goh KL (2007) Changing trends in gastrointestinal disease in the Asia-Pacific region. J Dig Dis 8:179–185. doi:10.1111/j.1751-2980.2007.00304.x CrossRefPubMed

35.

Guarner F, Lázaro, Gascón, Royo, Eximan, Herrero (2008) Map of digestive disorders & diseases. World Gastroenterology Organisation. http://www.worldgastroenterology.org/assets/downloads/pdf/wdhd/2008/events/map_of_digestive_disorders_2008.pdf. Accessed 25 Feb 2015

36.

Ghoshal UC, Singh R, Chang FY, Hou X, Wong BC, Kachintorn U, Functional Dyspepsia Consensus Team of the Asian N, Motility A, the Asian Pacific Association of G (2011) Epidemiology of uninvestigated and functional dyspepsia in Asia: facts and fiction. J Neurogastroenterol Motil 17:235–244. doi:10.5056/jnm.2011.17.3.235 CrossRefPubMedPubMedCentral

37.

Clemens S, Begum N, Harper C, Whitty JA, Scuffham PA (2014) A comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA. Qual Life Res 23:2375–2381. doi:10.1007/s11136-014-0676-x CrossRefPubMed

38.

Self-Reported Population Health: an international perspective based on EQ-5D (2014). 1 edn. Springer: Netherlands

39.

Yu ST, Chang HY, Yao KP, Lin YH, Hurng BS (2015) Validity of EQ-5D in general population of Taiwan: results of the 2009 National Health Interview and drug abuse survey of Taiwan. Qual Life Res 24:2541–2548. doi:10.1007/s11136-015-0978-7 CrossRefPubMed

Title: Impact of gastrointestinal events on patient-reported outcomes in Asia-Pacific women with osteoporosis: baseline results of the MUSIC OS-AP study
Authors: A. Modi
P. R. Ebeling
M. S. Lee
Y. K. Min
A. Mithal
X. Yang
S. Baidya
S. Sen
S. Sajjan
Publication date: 01-12-2017
Publisher: Springer London
Published in: Archives of Osteoporosis / Issue 1/2017
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-017-0350-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impact of gastrointestinal events on patient-reported outcomes in Asia-Pacific women with osteoporosis: baseline results of the MUSIC OS-AP study

Abstract

Summary

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Osteoporosis among hospitalized patients with proximal femoral fractures in Assiut University Trauma Unit, Egypt

The association of kyphosis assessed in supine and standing positions with future activities of daily living dependence: the Kurabuchi Study

Pregnancy-associated transient osteoporosis of the hip: results of a case-control study

Effect of health literacy on adherence to osteoporosis treatment among patients with distal radius fracture

Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States

Implementation of a fall screening program in a high risk of fracture population